New role for the anandamide metabolite prostaglandin F2α ethanolamide: Rolling preadipocyte proliferation
Journal of Lipid Research · 2023
DOI: 10.1016/j.jlr.2023.100444 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Lipid Research, 2023. Verfasst von Besma Boubertakh und 4 weiteren Autor:innen. Beteiligte Einrichtung: Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec (CRIUCPQ), Département de médecine, Faculté de Médecine, U…. Hauptthemen laut MEDLINE: Endocannabinoids, PPAR gamma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canada First Research Excellence Fund, Canada Excellence Research Chairs, Government of Canada.
Abstract (Originalsprache)
White adipose tissue regulation is key to metabolic health, yet still perplexing. The chief endocannabinoid anandamide metabolite, prostaglandin F2α ethanolamide (PGF2αEA), inhibits adipogenesis, that is, the formation of mature adipocytes. We observed that adipocyte progenitor cells-preadipocytes-following treatment with PGF2αEA yielded larger pellet sizes. Thus, we hypothesized that PGF2αEA might augment preadipocyte proliferation. Cell viability MTT and crystal violet assays, cell counting, and 5-bromo-2'-deoxyuridine incorporation in cell proliferation ELISA analyses confirmed our prediction. Additionally, we discovered that PGF2αEA promotes cell cycle progression through suppression of the expression of cell cycle inhibitors, p21 and p27, as shown by flow cytometry and qPCR. Enticingly, concentrations of this compound that showed no visible effect on cell proliferation or basal transcriptional activity of peroxisome proliferator-activated receptor gamma could, in contrast, reverse the anti-proliferative and peroxisome proliferator-activated receptor gamma-transcription activating effects of rosiglitazone (Rosi). MTT and luciferase reporter examinations supported this finding. The PGF2αEA pharmaceutical analog, bimatoprost, was also investigated and showed very similar effects. Importantly, we suggest the implication of the mitogen-activated protein kinase pathway in these effects, as they were blocked by the selective mitogen-activated protein kinase kinase inhibitor, PD98059. We propose that PGF2αEA is a pivotal regulator of white adipose tissue plasticity, acting as a regulator of the preadipocyte pool in adipose tissue.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec (CRIUCPQ), Département de médecine, Faculté de Médecine, Université Laval, Québec, Canada; Institut sur la Nutrition et les Alim…
- Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec (CRIUCPQ), Département de médecine, Faculté de Médecine, Université Laval, Québec, Canada.
Förderung
- Canada First Research Excellence Fund
- Canada Excellence Research Chairs, Government of Canada
Zitieren
APA
Boubertakh, B., Courtemanche, O., Marsolais, D., Di Marzo, V., & Silvestri, C. (2023). New role for the anandamide metabolite prostaglandin F2α ethanolamide: Rolling preadipocyte proliferation. Journal of Lipid Research. https://doi.org/10.1016/j.jlr.2023.100444
Vancouver
Boubertakh B, Courtemanche O, Marsolais D, Di Marzo V, Silvestri C. New role for the anandamide metabolite prostaglandin F2α ethanolamide: Rolling preadipocyte proliferation. Journal of Lipid Research. 2023. doi:10.1016/j.jlr.2023.100444
BibTeX
@article{Boubertakh2023,
author = {Boubertakh, Besma and Courtemanche, Olivier and Marsolais, David and Di Marzo, Vincenzo and Silvestri, Cristoforo},
title = {New role for the anandamide metabolite prostaglandin F2α ethanolamide: Rolling preadipocyte proliferation},
journal = {Journal of Lipid Research},
year = {2023},
doi = {10.1016/j.jlr.2023.100444}
}
EUVIMED